The Journal of Rheumatology最新文献

{"title":"GRAPPA Patient Research Partner Network Composition and Engagement: A Survey to Determine Strategic Areas for Growth.","authors":"Christine A Lindsay,Suzanne M Grieb,Arnon Katz","doi":"10.3899/jrheum.2025-0536","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0536","url":null,"abstract":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Patient Research Partner (PRP) Network conducted a survey to identify its key strengths and gaps, with the goal of enhancing its global reach and representation. The survey revealed strong gender parity and high long-term project participation among PRP members. However, it also indicated a need for greater ethnic and geographical diversity among the members. To address this, the PRP Network will expand its membership and specifically recruit partners from underrepresented regions such as Africa, Asia, Australia/New Zealand, South America, and Eastern Europe. Additionally, the network aims to expand its age range to include a more representative selection of research partners, thereby advancing GRAPPA's overarching objectives. The results of the survey were presented at the GRAPPA 2024 annual meeting.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis.","authors":"Fadi Kharouf,Ali AlHadri,Shangyi Gao,Daniel Pereira,Richard J Cook,Vinod Chandran,Dafna D Gladman","doi":"10.3899/jrheum.2025-0518","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0518","url":null,"abstract":"OBJECTIVESecondary failure to biologic DMARDs (bDMARDs) is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). We aimed to define the frequency and incidence of this phenomenon in PsA and identify the risk factors for its occurrence.METHODSWe retrieved data on PsA patients from our single-centre, specialized-care, prospective observational cohort who initiated and remained on bDMARDs for ≥1 year after clinic enrollment between 2000 and 2023. We defined response to therapy at the one-year visit (baseline) as achievement of ≥40% reduction in the swollen joint count (SJC) and either ≥50% reduction in PASI or PASI ≤2. We defined secondary failure as the inability to maintain response criteria or as the clinician's judgment of loss of effectiveness. To examine factors associated with secondary failure, we fitted Cox regression models.RESULTSOf 482 patients included in the study, 264 (54.8%) were responders at one year. Of these, 94 (35.6%) developed secondary failure at a median of 1.6 [IQR: 0.7, 3.8] years from response. In the multivariable model, higher SJC (HR 1.39, 95% CI 1.05-1.84) and PASI (HR 1.14, 95% CI 1.01-1.29) at baseline were associated with secondary failure. TNFi vs. other bDMARD use (HR 0.39, 95% CI 0.18-0.88), initiation as first-line bDMARD (HR 0.48, 95% CI 0.25-0.91), and treatment initiation during more recent calendar years (HR 0.34, 95% CI 0.12-0.98) were associated with less secondary failure.CONCLUSIONSecondary failure to bDMARDs is common in PsA and may be influenced by both disease- and therapy-related factors.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of ASAS criteria in Real-World Colombia SpA patients. A cross-sectional study.","authors":"Igor Rueda,Gustavo José Rodriguez,Ana María Santos,Juan Camilo Santacruz Devia,Sofía Arias-Correal,Keisy Orduz Uribe,Elias Quintero-Munoz,Cristian Mesa Pedraza,Juan Camilo Rueda,Juan Manuel Bello,Giovanny Ballesteros,Enrique Calvo,John Londono","doi":"10.3899/jrheum.2025-0073","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0073","url":null,"abstract":"OBJECTIVEThe Assessment of SpondyloArthritis international Society (ASAS) criteria classify spondyloarthritis (SpA) based on clinical presentation. Although widely applied, their performance in Colombia's population remains unclear. The study aimed to characterize a Colombian SpA cohort, identify factors associated with peripheral SpA (pSpA), compare SpA subtypes, assess the performance of ASAS criteria, and compare them with modified New York (mNY) and European Spondyloarthropathy Study Group (ESSG) criteria.METHODSThis cross-sectional study included patients with newly diagnosed SpA by at least one expert rheumatologist. Participants completed a structured survey, physical examination, imaging, and laboratory tests. Researchers classified patients using ASAS, ESSG, and mNY criteria and compared clinical characteristics across groups. Finally, the performance of the ASAS criteria relative to the rheumatologist's diagnosis, mNY, and ESSG.RESULTSThe study analyzed 461 SpA patients, of whom 58.1% had pSpA. Patients with axial SpA (axSpA) and pSpA differed significantly in age at onset, initial symptoms, buttock pain, Schober test, sacroiliitis, and HLA alleles. The ASAS criteria demonstrated a sensitivity of 90.8% compared to rheumatologist diagnosis. Notably, 33% of patients classified as ankylosing spondylitis by mNY or ESSG were misclassified as pSpA under ASAS due to unmet entry criteria for axSpA.CONCLUSIONThis large Colombian SpA cohort, predominantly pSpA, revealed distinct clinical and imaging features between axSpA and pSpA. The ASAS criteria showed high sensitivity but failed to classify a subset of patients with radiographic sacroiliitis as axSpA, highlighting limitations in their entry criteria for axSpA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related Quality of Life in DMARD-treated adults with Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population.","authors":"Imane Bardan,Till Uhlig,Joe Sexton,Tore Kristian Kvien,Gunnstein Bakland,Pawel Mielnik,Yi Hu,Øyvind Molberg,Anna-Birgitte Aga,Eirik Klami Kristianslund","doi":"10.3899/jrheum.2025-0384","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0384","url":null,"abstract":"OBJECTIVETo explore health-related quality of life (HRQoL) measured by Short Form 36 (SF-36), SF-36 physical component score (PCS), SF-36 mental component score (MCS) and Short Form 6D (SF-6D) in adults with juvenile idiopathic arthritis (JIA) compared to rheumatoid arthritis (RA) and the general population.METHODSWe used six-month follow-up data from the Norwegian disease-modifying antirheumatic drug study (NOR-DMARD), including adult JIA and RA patients starting or switching disease-modifying anti-rheumatic drug (DMARD) treatment. Age- and gender adjusted regression analyses were used to compare outcomes between JIA, RA and the general Norwegian population.RESULTSRegister data was available for 232 JIA- and 2764 RA patients at six months follow-up. JIA patients had poorer physical, but similar mental health as RA (adjusted difference (95% CI): PCS -3.58 (-6.09 to -1.08); MCS 2.02 (-0.51 to 4.54)). Compared to the general population, PCS scores were lower in both JIA and RA (adjusted differences; JIA-general population: -15.70 (-18.21 to -13.19), RA-general population: -12.12 (-12.76 to -11.47), but MCS was similar across groups. Average SF-6D utility levels were comparable in JIA and RA, but lower than the general population. Similar proportions of JIA and RA experienced improvements exceeding minimal clinical important difference (MCID) in SF-36 scale scores, PCS, MCS and SF-6D after six months.CONCLUSIONCompared to RA and the general population, JIA had lower physical HRQoL six months after DMARD initiation. Mental health composite scores were similar between JIA, RA and the general population. Both disease groups showed similar levels of improvement with treatment.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying resolution of clinically suspect arthralgia: a step towards understanding spontaneous reversal of an at-risk stage of rheumatoid arthritis.","authors":"Sarah J H Khidir,Elise van Mulligen,Annette H M van der Helm-van Mil","doi":"10.3899/jrheum.2025-0052","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0052","url":null,"abstract":"OBJECTIVESymptoms in the at-risk stage of clinically suspect arthralgia (CSA) can progress to Rheumatoid Arthritis (RA) or disappear spontaneously. The area of reversal of an at-risk stage is yet unexplored. Therefore, we aimed to determine its definition by evaluating patient-reported and rheumatologist-reported measures, and examine characteristics at baseline and over time of at-risk individuals with reversal.METHODS845 consecutively included CSA-patients were followed for 2 years. Reversal was assessed as patient-reported resolution of pain (pain-score≤20 on numerical rating scale (NRS 0-100) and as resolution of CSA, as defined by the rheumatologist (clinical outcomes recorded in medical records were obtained). Clinical and functional characteristics and MRIdetected subclinical joint-inflammation were studied over time.RESULTSAmong patients eligible for reversal, pain-resolution was achieved in 244/505 patients(48%) and rheumatologist-defined CSA-resolution in 357/505(71%). Patients with CSA-resolution but persistent pain, had pain from other causes than CSA/imminent-RA. Patients with pain-resolution without CSA-resolution, had remaining inflammatory symptoms (e.g. morning stiffness). Reversal of the at-risk stage was therefore best defined as rheumatologist-confirmed resolution of CSA. Patients achieving CSA-resolution had similar levels of subclinical joint-inflammation at presentation, but less pain, fatigue and morning stiffness than those without CSA-resolution. Over time, patients with CSA-resolution improved spontaneously in subclinical joint-inflammation (IRR=0.87/year, 95%CI=0.80-0.95,p=0.001) and functional disabilities (β=-0.07/year, 95%CI=-0.09 to -0.05,p<0.001).CONCLUSIONClinically, reversal of at-risk stage is better defined by rheumatologist-confirmed resolution of CSA, rather than a single patient-reported measure as pain. CSA-resolution associated with improved subclinical joint-inflammation and functional disabilities. This identification is a step towards investigating mechanisms underlying reversal of RA-risk.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classic Magnetic Resonance Imaging Features Unmask Progressive Multifocal Leukoencephalopathy in Rituximab-Treated Neuropsychiatric Systemic Lupus Erythematosus.","authors":"Cheng-Hsun Lin,Yu-Pang Lin","doi":"10.3899/jrheum.2025-0410","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0410","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting.","authors":"Maria-Angeliki Gkini,Lyn Chinchay,Chris A Lindsay,Manuel Franco,Juan Raul Castro Ayarza,Kristina Callis Duffin","doi":"10.3899/jrheum.2025-0606","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0606","url":null,"abstract":"Rheumatologists and other nondermatologists often encounter patients with psoriatic arthritis (PsA) who present with cutaneous diseases that mimic psoriasis (PsO). Cutaneous disorders including tinea, seborrheic dermatitis, eczema, pityriasis rubra pilaris, syphilis, or cutaneous lymphoma are commonly mistaken for PsO. It is crucial for rheumatologists and other nondermatologists to recognize alternative conditions and to consider referral to dermatology when skin disease is not responding to therapy. Correct diagnosis is important when assessing disease severity in clinical practice as well. Although the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are gold standards for physician- and patient-reported outcomes in clinical trials, they are not practical to deploy in busy clinical practice. Use of a physician global assessment (PGA), body surface area using a handprint method, and informal patient-reported outcomes can be useful in documenting the burden of disease. A treat-to-target approach using a PGA of clear/almost clear is ideal. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, a 2-part workshop was conducted for rheumatologists to first review skin disorders commonly mistaken for PsO, and second, to review outcome measures best suited for clinical practice.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Real-World Data for Studies of Dynamic Disease Processes.","authors":"Richard J Cook,Jerald F Lawless,Lily Zou","doi":"10.3899/jrheum.2025-0160","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0160","url":null,"abstract":"Obtaining valid real-world evidence about intervention effects from observational cohorts or administrative health records data is challenging. Visits to healthcare providers tend to occur more often during periods of increased disease activity and symptom exacerbation, or upon disease progression. Treatments likewise tend to change when it is apparent that disease activity has increased or a meaningful progression has occurred. This creates a dual problem that patient visits are disease-related, and treatments changes are driven by disease condition and clinical presentation. Disease-related visits and treatment by indication can produce a biased impression of the disease process in the target population and of the effects of treatment. We discuss how these challenges can be addressed through the use of joint models for the disease, marker and treatment processes, as well as the observation (visit) process. Using illustrative multistate models we demonstrate the biases that can arise from various types of analysis, and show how estimators from fitting such joint models to persons with psoriatic arthritis can be used to gain scientific insights and address common questions about treatment effects.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Representative Are Data From Clinical Trials in Axial Spondyloarthritis for Women?","authors":"Irene E van der Horst-Bruinsma,Sander I van Leuven","doi":"10.3899/jrheum.2025-0871","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0871","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Musculoskeletal Symptoms in Patients With Psoriasis: Who Should Be in the Driver's Seat?","authors":"Karen Briner,Pamela Diaz,Fabian Proft,Laura J Savage","doi":"10.3899/jrheum.2025-0237","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0237","url":null,"abstract":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting included a lively debate regarding the optimal management of musculoskeletal (MSK) symptoms in patients with psoriasis (PsO) at risk of or with early psoriatic arthritis (PsA). Drs. Fabian Proft and Laura Savage presented comprehensive, evidence-based retrospective arguments from the perspectives of rheumatology and dermatology. Proft advocated for rheumatologists to lead PsA management by highlighting the specialized training that allows rheumatologists to identify inflammatory diseases and use advanced imaging techniques to differentiate PsA from mechanical MSK conditions. In contrast, Savage emphasized the pivotal role of dermatologists, who often serve as the first healthcare providers (HCPs) to encounter emergent PsA in their patients with PsO. Dermatologists are increasingly aware of the importance of early detection and timely intervention, as well as of the new data that support the concept of \"treating to intercept\" in patients at risk of transition from PsO to PsA. Both experts highlighted systemic barriers hindering collaborative care and underscored the necessity of patient-centered approaches that effectively address skin and joint manifestations. This article summarizes the insightful debate, reinforcing the importance of a multidisciplinary approach to optimize patient outcomes with PsA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}